ahlam1399
09-23-2015, 09:50 PM
GSK may get EU green light for new biotech asthma drug this week
LONDON (Reuters) - GlaxoSmithKline may get a green light from European regulators as early as this week for a new biotech medicine to treat severe asthma, boosting prospects for its struggling respiratory business.
http://rc.feedsportal.com/r/238386230055/u/49/f/654207/c/35217/s/4a1a3bf9/sc/28/rc/1/rc.img (http://rc.feedsportal.com/r/238386230055/u/49/f/654207/c/35217/s/4a1a3bf9/sc/28/rc/1/rc.htm)
http://rc.feedsportal.com/r/238386230055/u/49/f/654207/c/35217/s/4a1a3bf9/sc/28/rc/2/rc.img (http://rc.feedsportal.com/r/238386230055/u/49/f/654207/c/35217/s/4a1a3bf9/sc/28/rc/2/rc.htm)
http://rc.feedsportal.com/r/238386230055/u/49/f/654207/c/35217/s/4a1a3bf9/sc/28/rc/3/rc.img (http://rc.feedsportal.com/r/238386230055/u/49/f/654207/c/35217/s/4a1a3bf9/sc/28/rc/3/rc.htm)
http://da.feedsportal.com/r/238386230055/u/49/f/654207/c/35217/s/4a1a3bf9/sc/28/a2.img (http://da.feedsportal.com/r/238386230055/u/49/f/654207/c/35217/s/4a1a3bf9/sc/28/a2.htm)
http://adchoice.feedsportal.com/r/238386230055/u/49/f/654207/c/35217/s/4a1a3bf9/sc/28/ach.img (http://adchoice.feedsportal.com/r/238386230055/u/49/f/654207/c/35217/s/4a1a3bf9/sc/28/ach.htm)http://pi.feedsportal.com/r/238386230055/u/49/f/654207/c/35217/s/4a1a3bf9/sc/28/a2t.imghttp://pi2.feedsportal.com/r/238386230055/u/49/f/654207/c/35217/s/4a1a3bf9/sc/28/a2t2.imghttp://i0.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/4a1a3bf9/sc/28/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=Wd_J_P6M2M8:kkszUIW_T_w:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=Wd_J_P6M2M8:kkszUIW_T_w:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=Wd_J_P6M2M8:kkszUIW_T_w:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=Wd_J_P6M2M8:kkszUIW_T_w:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=Wd_J_P6M2M8:kkszUIW_T_w:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/Wd_J_P6M2M8
LONDON (Reuters) - GlaxoSmithKline may get a green light from European regulators as early as this week for a new biotech medicine to treat severe asthma, boosting prospects for its struggling respiratory business.
http://rc.feedsportal.com/r/238386230055/u/49/f/654207/c/35217/s/4a1a3bf9/sc/28/rc/1/rc.img (http://rc.feedsportal.com/r/238386230055/u/49/f/654207/c/35217/s/4a1a3bf9/sc/28/rc/1/rc.htm)
http://rc.feedsportal.com/r/238386230055/u/49/f/654207/c/35217/s/4a1a3bf9/sc/28/rc/2/rc.img (http://rc.feedsportal.com/r/238386230055/u/49/f/654207/c/35217/s/4a1a3bf9/sc/28/rc/2/rc.htm)
http://rc.feedsportal.com/r/238386230055/u/49/f/654207/c/35217/s/4a1a3bf9/sc/28/rc/3/rc.img (http://rc.feedsportal.com/r/238386230055/u/49/f/654207/c/35217/s/4a1a3bf9/sc/28/rc/3/rc.htm)
http://da.feedsportal.com/r/238386230055/u/49/f/654207/c/35217/s/4a1a3bf9/sc/28/a2.img (http://da.feedsportal.com/r/238386230055/u/49/f/654207/c/35217/s/4a1a3bf9/sc/28/a2.htm)
http://adchoice.feedsportal.com/r/238386230055/u/49/f/654207/c/35217/s/4a1a3bf9/sc/28/ach.img (http://adchoice.feedsportal.com/r/238386230055/u/49/f/654207/c/35217/s/4a1a3bf9/sc/28/ach.htm)http://pi.feedsportal.com/r/238386230055/u/49/f/654207/c/35217/s/4a1a3bf9/sc/28/a2t.imghttp://pi2.feedsportal.com/r/238386230055/u/49/f/654207/c/35217/s/4a1a3bf9/sc/28/a2t2.imghttp://i0.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/4a1a3bf9/sc/28/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=Wd_J_P6M2M8:kkszUIW_T_w:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=Wd_J_P6M2M8:kkszUIW_T_w:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=Wd_J_P6M2M8:kkszUIW_T_w:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=Wd_J_P6M2M8:kkszUIW_T_w:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=Wd_J_P6M2M8:kkszUIW_T_w:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/Wd_J_P6M2M8